Display options
Cite
Laguio-Vila MR, Thompson MG, Reynolds S, et al. Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel. Open Forum Infect Dis. 2015;2(1):ofu115doi: 10.1093/ofid/ofu115.
Laguio-Vila, M. R., Thompson, M. G., Reynolds, S., Spencer, S. M., Gaglani, M., Naleway, A., Ball, S., Bozeman, S., Baker, S., Martínez-Sobrido, L., Levine, M., Katz, J., Fry, A. M., & Treanor, J. J. (2015). Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel. Open forum infectious diseases, 2(1), ofu115. https://doi.org/10.1093/ofid/ofu115
Laguio-Vila, Maryrose R, et al. "Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel." Open forum infectious diseases vol. 2,1 (2015): ofu115. doi: https://doi.org/10.1093/ofid/ofu115
Laguio-Vila MR, Thompson MG, Reynolds S, Spencer SM, Gaglani M, Naleway A, Ball S, Bozeman S, Baker S, Martínez-Sobrido L, Levine M, Katz J, Fry AM, Treanor JJ. Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel. Open Forum Infect Dis. 2015 Jan 03;2(1):ofu115. doi: 10.1093/ofid/ofu115. eCollection 2015 Jan. PMID: 25884004; PMCID: PMC4396428.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2015 Jan 03;2(1):ofu115. doi: 10.1093/ofid/ofu115. eCollection 2015 Jan.

Comparison of serum hemagglutinin and neuraminidase inhibition antibodies after 2010-2011 trivalent inactivated influenza vaccination in healthcare personnel.

Open forum infectious diseases

Maryrose R Laguio-Vila, Mark G Thompson, Sue Reynolds, Sarah M Spencer, Manjusha Gaglani, Allison Naleway, Sarah Ball, Sam Bozeman, Steven Baker, Luis Martínez-Sobrido, Min Levine, Jackie Katz, Alicia M Fry, John J Treanor

Affiliations

  1. Division of Infectious Diseases.
  2. Epidemiology and Prevention Branch , Influenza Division/National Center for Immunization and Respiratory Diseases/Centers for Disease Control and Prevention , Atlanta, Georgia.
  3. Division of Pediatric Infectious Diseases , Baylor Scott and White Health , Temple, Texas.
  4. The Center for Health Research , Kaiser Permanente Northwest , Portland, Oregon.
  5. Abt Associates , Cambridge Massachusetts.
  6. Department of Microbiology and Immunology , University of Rochester Medical Center , New York.

PMID: 25884004 PMCID: PMC4396428 DOI: 10.1093/ofid/ofu115

Abstract

Background.  Most inactivated influenza vaccines contain purified and standardized hemagglutinin (HA) and residual neuraminidase (NA) antigens. Vaccine-associated HA antibody responses (hemagglutination inhibition [HAI]) are well described, but less is known about the immune response to the NA. Methods.  Serum of 1349 healthcare personnel (HCP) electing or declining the 2010-2011 trivalent-inactivated influenza vaccine ([IIV3], containing A/California/7/2009 p(H1N1), A/Perth/16/2009 [H3N2], B/Brisbane/60/2008 strains) were tested for NA-inhibiting (NAI) antibody by a modified lectin-based assay using pseudotyped N1 and N2 influenza A viruses with an irrelevant (H5) HA. Neuraminidase-inhibiting and HAI antibody titers were evaluated approximately 30 days after vaccination and end-of-season for those with polymerase chain reaction (PCR)-confirmed influenza infection. Results.  In 916 HCP (68%) receiving IIV3, a 2-fold increase in N1 and N2 NAI antibody occurred in 63.7% and 47.3%, respectively. Smaller responses occurred in HCP age >50 years and those without prior 2009-2010 IIV3 nor monovalent A(H1N1)pdm09 influenza vaccinations. Forty-four PCR-confirmed influenza infections were observed, primarily affecting those with lower pre-exposure HAI and NAI antibodies. Higher pre-NAI titers correlated with shorter duration of illness for A(H1N1)pdm09 virus infections. Conclusions.  Trivalent-inactivated influenza vaccine is modestly immunogenic for N1 and N2 antigens in HCP. Vaccines eliciting robust NA immune responses may improve efficacy and reduce influenza-associated morbidity.

Keywords: antibody; hemagglutinin-inhibition; influenza; neuraminidase-inhibition; vaccine

References

  1. J Infect Dis. 2010 Dec 1;202(11):1634-8 - PubMed
  2. PLoS One. 2012;7(3):e33048 - PubMed
  3. J Gen Virol. 2012 Sep;93(Pt 9):1996-2007 - PubMed
  4. N Engl J Med. 1972 Jun 22;286(25):1329-32 - PubMed
  5. Adv Immunol. 1968;8:81-127 - PubMed
  6. Vaccine. 2010 Feb 25;28(9):2076-9 - PubMed
  7. J Virol Methods. 2011 May;173(2):364-73 - PubMed
  8. JAMA. 2000 Oct 4;284(13):1655-63 - PubMed
  9. J Virol. 1989 Mar;63(3):1239-46 - PubMed
  10. Vaccine. 2001 Sep 14;19(32):4610-7 - PubMed
  11. Virology. 1983 Oct 30;130(2):539-45 - PubMed
  12. J Infect Dis. 2014 Jun 1;209(11):1705-14 - PubMed
  13. Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20748-53 - PubMed
  14. N Engl J Med. 2005 Sep 29;353(13):1363-73 - PubMed
  15. Vaccine. 2006 Feb 20;24(8):1159-69 - PubMed
  16. J Clin Microbiol. 1986 Jul;24(1):157-60 - PubMed
  17. J Virol. 2010 Feb;84(4):2157-63 - PubMed
  18. Vaccine. 2003 May 1;21(16):1776-9 - PubMed
  19. Arch Intern Med. 2006 May 22;166(10):1121-7 - PubMed
  20. Clin Infect Dis. 2011 Dec;53(12):1179-87 - PubMed
  21. Vaccine. 2000 Aug 1;18(28):3214-22 - PubMed
  22. J Virol. 2013 Aug;87(15):8591-605 - PubMed
  23. PLoS Med. 2007 Feb;4(2):e59 - PubMed
  24. J Infect Dis. 2013 Mar 15;207(6):974-81 - PubMed
  25. J Immunol Methods. 1990 Dec 31;135(1-2):49-57 - PubMed
  26. Vaccine. 2012 Dec 17;31(1):190-5 - PubMed
  27. N Engl J Med. 2009 Nov 12;361(20):1945-52 - PubMed
  28. J Infect Dis. 1999 Jan;179(1):31-6 - PubMed
  29. J Infect Dis. 2006 Nov 1;194 Suppl 2:S147-54 - PubMed
  30. Lancet. 1973 Mar 24;1(7804):623-5 - PubMed
  31. J Virol. 1993 Oct;67(10):5721-3 - PubMed
  32. J Infect Dis. 2009 Jul 15;200(2):172-80 - PubMed

Publication Types

Grant support